Under the partnership, both firms will start a research and development collaboration at AstraZeneca’s Innovation Campus (iCampus) in Chengdu, China
Yiviva and AstraZeneca China collaborate on botanical medicines and systems biology platforms development. (Credit: GlobeNewswire/ Yiviva)
Yiviva, a biotechnology firm developing medicines for ageing-related diseases, has signed a memorandum of understanding (MoU) with AstraZeneca China to develop platforms, technologies, and therapeutics through a systems biology approach.
Under the partnership, both firms will start a research and development collaboration at AstraZeneca’s Innovation Campus (iCampus) in Chengdu, China.
Together, Yiviva and AstraZeneca China will create platforms for academic and industrial development and scientific research transformation to address global unmet medical needs.
The MoU is intended to modernise botanical medicines in compliance with the China National Medical Products Administration (NMPA) and the US Food and Drug Administration (FDA)’s new regulatory pathways for botanical medicines.
AstraZeneca China vice president Lily Zhu said: “In collaboration with the Chengdu government and Chengdu High-Tech Industrial Zone (CDHT), AstraZeneca is establishing a modern healthcare development platform integrating traditional Chinese medicine and Western medicine.
“At CIIE, AstraZeneca announced plans to further globalise Chinese medicine. Our strategic partnership with Yiviva will advance our blueprint for how to develop innovative medicines inspired by Chinese medicine.”
Yiviva has a STAR (signal transduction, activity and response) drug discovery platform designed to expedite the detection of botanical therapeutics that control immune function, inflammatory responses, cell growth, metabolic functions, and hormone activity.
The biotechnology firm can create complex multi-target medications that correspond to complicated disease biology by using the STAR platform.
The company has discovered six first-in-class drug candidates for the treatment of inflammatory illnesses and cancer.
Yiviva co-founder and CEO Peikwen Cheng said: “By bringing together the knowledge and best practices of Western and Eastern Medicine, WE Medicine, we can learn from ancient wisdom to develop future medicines.
“Together with AstraZeneca China’s expertise, ecosystem, and resources, and Yiviva’s team, platform technologies, and pipeline, we can pioneer a new paradigm for systems biology drug development to address global unmet medical needs.”